Halozyme Therapeutics reports a record Q2 2025, with 41% revenue growth. Discover raised guidance, strong catalysts, and shareholder-focused initiatives.

The One Nasdaq approach continued to accelerate cross-selling opportunities, with the company on track to surpass $100 million in run-rate revenue from cross-sells by the end of 2027. Cross-sells now ...

Being an address by Akutah Pius Ukeyima, executive secretary/CEO, Nigerian Shippers’ Council (NSC), at The ICC Nigeria Post ...

Q2 2025 Earnings Call Transcript July 29, 2025 Incyte Corporation beats earnings expectations. Reported EPS is $2.04, ...

EAC certification is a mandatory requirement for entering the EAEU market. Products that have not passed EAC certification cannot be legally sold in Russia, Belarus, Kazakhstan, Armenia, and ...

Nasdaq, Inc. (Nasdaq: NDAQ) today reported financial results for the second quarter of 2025. Second quarter 2025 net revenue1 was $1.3 billion, an increase of 13% over the second quarter of 2024, or ...

Q2 2025 Earnings Conference Call July 31, 2025 8:30 AM ETCompany ParticipantsBrian Foard - Executive VP & Head of ...

ASP Isotopes Inc. NASDAQ: ASPI ('ASP Isotopes” or the 'Company”), an advanced materials company dedicated to the development ...

India remains engaged with the United States on a trade deal, an Indian government source familiar with the matter told ...

The IFSCA has issued new regulations for TechFin and Ancillary Service Providers in International Financial Services Centres, ...

Under the Agreement, the Company has agreed to acquire Copperline in exchange for (i) cash, (ii) common shares of the Company ("Common Shares"), (iii) the grant of the Net Smelter Royalty (as defined ...